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nature of neurotransmission (see Fraidakis, 2010). Arguably, Lugaro
was also the ﬁrst to suggest that CNS white matter actively inhibits
axon regeneration. His “Negative neurotropism” hypothesis was based
on his ﬁndings that motor axons could regenerate in the dorsal root
but only as far as the dorsal root entry zone, where they were instead
repulsed and took other routes, such as in the pia mater. Martin Berry
obtained early experimental support for the inhibitory effect of CNSmy-
elin (Berry, 1982). The the pioneering work of Martin Schwab and hisIt has long been known that injured axons in the brain and spinal
cord of adult mammals do not regenerate. It has been known almost
as long, that the lack of such axon regeneration is not due to an intrinsic
inability of adult mammalian CNS neurons to regenerate axons, but
rather to the non-permissiveness of the immediate surroundings of
the injured axons. After axotomy in the CNS very local sprouting,
termed “abortive sprouting” by Ramón y Cajal, can be seen to emerge
from both ends of a cut axon, (see Ramón y Cajal, 1928; Olson, 1997),
but such sprouts do not elongate in white matter. For an exposé of the
early days and the proponents of negative neurotropism, not the least
the work of Lugaro, and the fact that CNS axons can, but are typically
inhibited from regeneration, see Fraidakis, (2010). A compelling dem-
onstration of regeneration of adult mammalian CNS axons exposed to
the environment of peripheral nerve tissue was provided by Tello,
who showed that axon bundles invaded grafts of pieces of peripheral
nerves placed in the cerebral cortex of rabbits, and that axon growth
into the grafts was better and followed the bands of Büngner, if the
nerve grafts had been predegenerated (Tello, 1911). The source of the
“neurotropic substances” was thought to be Schwann cells (Marinesco,
1906). Implantation of peripheral nerve grafts into theCNSwas repeated
in the 40s (Le Gros Clark, 1943) and the possible use of peripheral nerve
grafts as bridging conduits for regenerating CNS axons was demonstrat-
ed by Aguayo and collaborators (Richardson et al., 1980). Later, multiple
bridges of peripheral nerves across a complete transection of the spinal
cord were shown to allow a degree of functional recovery in adult rats
(Cheng et al., 1996, 1997; Lee et al., 2002, 2004; Tsai et al., 2005).
Inhibitors of axon regeneration
Ernesto Lugaro (1870–1940) was a prominent neuroscientist of
his time, supporting the Neuron Doctrine as proposed by Waldeyer
(1891) and Cajal's Neurotropism hypothesis. He found the cerebellarc. Open access under CC BY-NC-ND licensecollaborators (Caroni and Schwab, 1988a; Caroni and Schwab, 1988b,
see also Schwab, 2010; Petersen et al., 2012a, 2012b; Karlsson et al.,
2013) ﬁnally led to the identiﬁcation of an inhibitory component ofmy-
elin and the cloning of the Nogo gene (Chen et al., 2000; Prinjha et al.,
2000; GrandPre et al., 2000), which was followed by cloning of the
ﬁrst Nogo receptor (Fournier et al., 2001). There has been a formidable
recent development of this ﬁeld, with the discovery of the additional in-
hibitors inmyelin,MAG (McKerracher et al., 1994;Mukhopadhyay et al.,
1994) and OMgp (Wang et al., 2002b), the Nogo receptors NgR2 and
NgR3 (Laurén et al., 2003, 2007), and additional receptors, coreceptors
and interacting proteins, including p75 (Wang et al., 2002a), Lingo (Mi
et al., 2004), Troy (Park et al., 2005; Shao et al., 2005), PirB (Syken
et al., 2006; Atwal et al., 2008), and Lotus (Sato et al., 2011), and addi-
tional components of the complex signaling systems that regulate
growth and plasticity in the central nervous system (Borrie et al.,
2012; Dickendesher et al., 2012; Schwab, 2010).Shifting focus from white to gray matter
Having identiﬁed Nogo as a key inhibitory protein of CNSmyelin,
there was a focus on Nogo's role in white matter and the possibili-
ties that Nogo inhibition might offer to stimulate long distance
axon regeneration. It was then found that Nogo is expressed not
only by oligodendrocytes, but by many neurons as well (Josephson
et al., 2001b), and that NgR1 was exclusively expressed by neurons
(Fournier et al., 2001; Josephson et al., 2002). Moreover, NgR
mRNA expression is promptly down-regulated by increased neuro-
nal activity (Josephson et al., 2003). It was thus hypothesized
that temporary NgR1 down-regulation could be important for syn-
aptic plasticity underlying the formation of lasting memories and
the idea obtained support in a transgenic mouse with inducible
activity-insensitive expression of a NgR1 transgene in forebrain
neurons (Karlén et al., 2009). Importantly, mice lacking NgR1
were found to maintain ocular dominance shift plasticity into adult-
hood (McGee et al., 2005). While these ﬁndings and similar obser-
vations in Nogo A knockout mice were interpreted as due to a role..
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(Josephson et al., 2001b) suggests that the increased plasticity in
adult mice lacking either NgR1 or Nogo A is caused by increased
plasticity at the synaptic level in gray matter (see Akbik et al.,
2012; Pernet and Schwab, 2012).
The fact that interfering with Nogo–NgR signaling is likely to have ef-
fects not only in white, but also in gray matter has helped interpretation
of animal models of incomplete spinal cord injury. Thus rather than long
distance regeneration of axons in white matter, which is hindered not
only by the presence of Nogo, but also at the site of injury by several com-
ponents of local scarring, sprouting from remaining axon systems, dis-
tant from the lesion site, and even onto other non-injured neurons,
able to relay signals within the spinal cord, has been demonstrated to
occur and have functional effects (see Petersen et al., 2012a, 2012b).
Moreover, plastic changes in response to spinal cord injury also occur
in the brain, in a manner that involves local down-regulation of NgR1
(Endo et al., 2007).The complex pathology of spinal cord injury
The normal nerve growth forbidding CNS environment described
above is the context in which trauma to the CNS should be under-
stood. After trauma to the spinal cord, the damaged tissue undergoes
a series of pathological and reactive alterations, most of which serve
to contain the damage, avoid infection, and take care of debris, rather
than to actively support recovery. A plethora of cells, including activated
astrocytes, activated microglia, proliferating pericytes, macrophages
and other cells of the immune system enter the damaged area and its
surroundings. A breach in the blood-spinal cord barrier causes leakage
of proteins and other blood components (see Abrams et al., 2012),
dead and damaged cells will be present, edemas will form and can
lead to cysts (Josephson et al., 2001a), and excess chondroitin sulphate
proteoglycans (CSPGs) become deposited in the extracellular space
(Morgenstern et al., 2002; Sharma et al., 2012). Digestion of CSPGs has
proven an effectivemeans to enhance nerve ﬁber growth and sprouting
after injury (Bradbury et al., 2002; Starkey et al., 2012). This supports
previous observations that microtransplants of adult sensory neurons,
small enough not to evoke a CSPG scar formation, are able to regenerate
long axons in intact as well as actively degenerating spinal cord white
matter (Davies et al., 1999), even though such neurons may express
NgR1 (Josephson et al., 2001a, 2001b).
Ischemia and other adverse circumstances at the site of injury may
also lead to the death of oligodendrocytes needed to support non-
disrupted axons in the traumatized area. Such spared sets of locally
demyelinated axons, supported by their distant cell bodies, constitute
an important target for treatment aimed at improving their conduction
properties and their long term survival by the provision of new myelin
sheaths.
Importantly, a localized spinal cord injury will also lead to distant
effects. Degeneration of ascending and descending axons, interrupted
at the injury site, will cause white matter pathology at many levels.
Masses of myelin sheaths will have to be phagocytized. For instance,
reactive astrocytes with increased GFAP immunoreactivity will be
found along almost the entire length of the injured rat spinal cord
for a long period of time (Widenfalk et al., 2001).
A thoracic injury will cause silencing of sensory inputs to the brain
from the hind limbs. This will elicit compensatory changes of cortical
circuitry, including decreased NgR expression, and increased BDNF
expression in the corresponding and neighboring cortical areas, pre-
sumably to allow plastic changes, prioritizing forelimb inputs (Endo
et al., 2007). Such plasticity, while useful if the spinal cord remains
severed, may become a hindrance to the reestablishment of a normal
cortical input if the spinal cord is later repaired. Severe injury will also
cause deterioration of health, including muscle wasting, and there
will be the risk of decubitus ulcers and urinary infections.Treatment strategies
There are no drugs with robust effects available for clinical use in
spinal cord injury. However, there are several ﬁnished and ongoing
clinical trials of different drugs for neuroprotection or to stimulate
regeneration, as well as trials of cell engraftment procedures (Sahni
and Kessler, 2010; Gensel et al., 2011; Fehlings et al., 2011; Casha
et al., 2012; Tabakow et al., 2013). Ongoing trials include delivery of
Nogo antibodies (Filli and Schwab, 2012). Other trials will hopefully
start soon. Thus oral monotreatment with Imatinib (Glivec) leads to
improved recovery from spinal cord injury in rats (Abrams et al.,
2012). The fact that imatinib is in routine clinical use for other indica-
tions (cancer), should shorten the road to clinical trials of this partic-
ular drug in spinal cord injury.
How should one go about attempting to minimize the effects
of spinal cord injury? Very soon after incomplete injury, treatments
may help protect damaged spinal tissue, including its most important
elements, the white matter axon bundles, from secondary injury
occurring in the ﬁrst few weeks after the primary injury. While such
protection will not restore any communication across injury if the
cranial and caudal parts of the spinal cord are completely separated,
a neuroprotective regimen could still be beneﬁcial, perhaps rescuing
certain functions at the distal end of the cranial stump and setting
the stage for other future treatments aimed to bridge the communica-
tion gap.
Interruption of ascending and descending axon pathways will
cause permanent functional impairments. In addition to the attempts
to rescue as many axons as possible, there are therefore also several
approaches aiming at stimulating regeneration of cut axons and
provide them with biological or artiﬁcial bridging scaffolds. Recently,
efforts have also been made to bypass injury by electronic devices and
interfaces. Finally, there are treatments that encourage compensatory
terminal sprouting and other structural rearrangements at different
levels of the neuraxis.
Evolution is unlikely to have developed a system to actively inhibit
long distance axon regeneration in the adultmammalian central nervous
system. Other roles for the Nogo system in white matter therefore need
to be worked out, such as the arrangement of the oligodendrocyte-
derived myelin sheath (Chong et al., 2012). Nevertheless, the inhibitors
are so powerful, that they are difﬁcult to overcome by mere delivery of
known nerve growth stimulatory factors. Inhibition of Nogo signaling
has proven helpful in different models of CNS injury, such as spinal
cord injury (see Liebscher et al., 2005; Cafferty et al., 2010) and stroke
(see Tsai et al., 2011 and references therein). Experimentally, Nogo
signaling can be blocked at different levels, using gene deletion strate-
gies, blocking Nogo antibodies, NgR antibodies or a soluble NgR decoy
strategy. Alternatively, as the intracellular pathways become known,
downstream (see Kopp et al., 2012) and possibly upstream intervention
strategies could be developed.
Treatment with one drug does not reveal its full potential
The majority of experimental SCI treatment studies investigate the
effect of a single treatment. In the often used weight drop injury
model, several different drugs show effects of a similar magnitude,
almost as if therewas a ceiling effect, perhaps due to rescue of remaining
demyelinated but initially non-interrupted axons, which can presum-
ably be achieved in a number of different ways. If this were the cause
of the seemingly similar, relatively modest positive effects of a number
of different drugs, it would not help to combine such drugs. Instead, to
obtain additive or synergistic effects one needs to combine treatments
targeting different mechanisms. However, as soon as treatments/drugs
are combined, matters get complicated.
A single treatment/drug can have a net effect that ranges from neg-
ative, via no detectable effect to positive. In neither case will the poten-
tially useful effects of a given treatment/drug be fully understood from a
311L. Olson / Experimental Neurology 248 (2013) 309–315single mono-treatment study, if a combinatorial treatment is planned.
When two drugs are combined, they may act independently of each
other (additive effect, 1 + 1 = 2), or, if targeting the samemechanism,
not have additive effects (1 + 1 = 1). Alternatively, the two drugsmay
lead to synergistic effects (larger than the sum of the two individual
drugs, 1 + 1 = 3), or interact negatively (1 + 1 = 0). In addition,
there may be situations in which neither of two drugs is effective
alone, while the combination has an effect (0 + 0 = 1) or when one
drug without effect on its own can become effective when combined
with a second drug (0 + 1 = 2). In fact, when two drugs, each with
the possibility to exert one of three effects (−1, 0, 1) are combined,
and additive, positive and negative synergy effects are taken into ac-
count, the number of possible outcomes increases rapidly. It follows
that combining 3 or more drugs/treatments is associated with a cor-
respondingly larger number of possible outcomes. To simplify the chal-
lenge of combining treatments onemay focus on combining treatments
that, when used as single treatments, have positive effects and are
unlikely to interact with each other. With regard to combining drugs/
treatments that are unlikely to exert negative effects, a reasonable
approach is to begin by combining several, and then systematically
removing drugs/treatments until it affects outcome negatively.
In spinal cord injury many things go awry. It is thus highly unlikely
that a treatment based on a single intervention, such as one drug or
one type of cell implantation, would be able to counteract all or
most aspects of the damage. Accordingly, an increasing number of
experimental studies have combined different treatments to obtain
better recovery. Promising results of combining trophic factors and
cellular elements in different ways have been reported (see reviews
by Blesch et al., 2002; Kwon and Tetzlaff, 2001; Fortun et al., 2009).
Examples of recent work include the use of GDNF-expressing Schwann
cells to stimulate nerve growth and recovery (Deng et al., 2013),
delivery of BDNF and chondroitinase to enhance regeneration through
peripheral nerve grafts (Tom et al., 2013), combining acidic FGF with
peripheral nerve grafts to improve gait after complete spinal cord tran-
section (Lee et al., 2010), or, when also adding chondroitinase, to re-
store bladder function (Lee et al., 2013), combining adult neural stem/
progenitor cells with growth factors and chondroitinase to promote
repair of the chronically injured spinal cord (Karimi-Abdolrezaee et
al., 2010), and the use of neurotrophin-secreting Schwann cells and
Rolipram to promote recovery (Flora et al., 2012).
Injury to the CNS differs from injury to other organs in that the
speciﬁc blood-brain barrier or blood-spinal cord barrier is breached.
CNS injury also differs from injury to other organs by being contained
within a non-expandable bone compartment such that bleedings and
edema can have catastrophic consequences. One or more components
of an acute treatment should therefore be focused on dampening
inﬂammatory and immune responses, as well as normalizing the
blood-spinal cord barrier. A second goal should be to inhibit scar for-
mation and the deposition of increased amounts of CSPG. As men-
tioned elsewhere in this review, enzymatic digestion of CSPGs has
proven remarkably helpful as a means to remove one key obstacle
to nerve ﬁber growth. There is recent evidence that the CSPGs not
only provide a physical barrier to nerve growth, but that these extra-
cellular proteins are also ligands to Nogo receptors NgR1 and NgR3
(Dickendesher et al., 2012). Because there is also widespread expres-
sion of Nogo, MAG and OmGP in myelin and of Nogo in neurons,
different ways to block Nogo receptor mediated nerve growth inhibi-
tion have been shown to improve nerve ﬁber growth. Additional
approaches that can be combined with all of the above include deliv-
ery of neurotrophic factors, providing scaffolds for nerve ﬁber growth,
either biological such as peripheral nerve grafts, or artiﬁcial, as well as
delivery of many different types of cells, to provide trophic support,
to help remyelinate denuded axons, to serve as a conduit for nerve
growth, or, in the form of neurons, to replace or substitute for lost
neuronal pathways. To these interventions should be added the value
of physical training programs.There are many examples of how different cell types used for
grafting have not been grafted in their native condition, but genetical-
ly altered to improve protective or reparative properties and diminish
possible negative effects (e.g. Hofstetter et al., 2005) and of a number
of other combinatorial approaches. In one model three treatments
with different targets were combined. The neurotrophin NT3 was
delivered by transgenic NT3-secreting ﬁbroblasts to stimulate nerve
growth, a viral construct was used to deliver the NR2D subunit of
the NMDA receptor to improve synaptic connectivity and injections
of chondroitinase ABC were used to remove extracellular CSPG
(García-Alías et al., 2011). Training has been combined with interven-
tional therapy such as ChABC (see García-Alías and Fawcett, 2012)
and is not always additive in combination with drug treatments
(Maier et al., 2009).
Combinatorial treatment for regeneration of sensory pathways
A recent experimental study published in this journal (Wang et al.,
2012) uses optic nerve and spinal cord crush models to examine this
issue. In both experiments, sensory nerve ﬁbers regenerating towards
the brain were investigated, originating from the retinal ganglion cells
and dorsal root ganglion cells, respectively. In the optic nerve model,
Wang and collaborators ﬁnd that while lack of Nogo receptor 1 or acti-
vation of macrophages and causing a sterile inﬂammation using an
intraocular zymosan A injection improves axon regeneration to about
the same degree, the combination of the two leads to synergistic effects
in terms of numbers of regenerating optic nerve axons (Fig. 1). This sup-
ports and extends earlier ﬁndings in the samemodel system (Fischer et
al., 2004).
Wang et al. went on to investigate combinatorial treatments in a
spinal cord dorsal column injury model, using a rather demanding
combination of drug delivery strategies (Fig. 2). They labeled ascend-
ing sensory tracts with CTB and found that three different single
treatments, icv delivery of Chondroitinase ABC (ChABC), infusion of
a soluble Nogo receptor decoy (NgR310-Fc) and preconditioning dor-
sal root ganglion cells by a sciatic nerve lesion, all stimulated regenera-
tion of ascending CTB-labeled ﬁbers to a degree. None of the three
possible paired treatments caused better regeneration, while the com-
bination of all three treatments caused longer axon regeneration. Re-
markably, the triple treatment allowed regenerating ﬁbers to extend
through and several millimeters beyond the site of injury (Fig. 1).
Wang et al. (2012) therefore suggests that combinatorial treatments
are of clinical interest, and likely to have better effects than any one sin-
gle treatment. While none of the two types of treatments studied in the
current optic nerve and spinal cord models could be fully used in a clin-
ical setting, they do add to the literature suggesting that counteracting
Nogo–NgR signaling can improve regeneration/sprouting in CNS tissue
and that both ChABC and preconditioning peripheral lesions can im-
prove central regeneration of sensory neurons. Wang et al. also investi-
gated if the sciatic nerve lesion could be carried out at the time of spinal
cord injury or even 3 days later. In both cases was there an effect, albeit
lesser than when the nerve had been lesioned a week before the spinal
cord.
Overall, it appears that ChABC treatment is an important constituent,
not only by allowing regenerating ﬁbers to cross the injury site, but also
by leading to a markedly increased number of labeled ﬁbers just caudal
of the injury site. The key role of digesting CSPGs (chondroitin sulphate
proteoglycans) in injury models is in line with the striking observations
by Silver and coworkers that neurons that are micrografted into adult
intact, or even degenerating white matter using a ﬁne glass pipette are
able to extend axons for long distances in the white matter, presumably
because the grafting technique does not elicit any activation of CSPG
deposition around the grafted neurons (Davies et al., 1997,1999). The
ﬁndings of Davies et al. provides support for the idea that the primary
role for Nogo in white matter tracts may not be to inhibit nerve growth,
although this may be important, e.g. at the nodes of Ranvier, in order to
Fig. 1. Regeneration studies in the optic nerve crush (left panel) and dorsal spinal cord
lesion (right panel) models used by Wang et al. (2012). In the optic nerve experiment,
numbers of regenerated ﬁbers at different distances from the lesion are shown for con-
trol mice (wt), NgR1−/− mice, as well as for these two genotypes given zymosan
(zym) into the posterior parts of the eye. In the spinal cord study, control IgG is com-
pared to preconditioning by a sciatic nerve lesion (PCI), delivery of a NgR decoy
(NgR), delivery of chodroitinase ABC (ChABC), the three possible pairwise combina-
tions of these three singe treatments, as well as the combination of all three treat-
ments. Figure composed from Figs. 2G and 9A in Wang et al. (2012), with permission.
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white matter may instead be due to the accumulation of CSPG material
at sites of injury. The microstereology of intact white matter may be
such that certain axons can indeed grow for long distances (Fig. 2).
The two regeneration experiments have one treatment in common,
ways to protect the regenerating axons from being inhibited by Nogo.
The optic nerve study accomplished this by the use of NgR1 knockout
mice. The spinal cord study was conducted in rats, and Nogo was
instead neutralized by delivery of a soluble NgR1 decoy, as pioneered
by the authors (Fournier et al., 2002). A difference between these two
approaches is that in the optic nerve experiment, Nogo will still be
able to bind to other receptors, such as NgR2, NgR3, PirB and other as
yet not deﬁned receptors,while in the spinal cord experiment, all effects
of Nogo are more or less inhibited, while instead possible effects of
other ligands, such as MAG and OMgp may remain.
As for activation of ganglion cells in the two model systems,
the authors used Zymosan for the retinal cells, and lesioning of the
peripheral axon for the dorsal root neurons. These two modes of
activation may possibly have some features in common, and while
axotomy is not an option in a clinical trial, activation by Zymosan or
other compounds could perhaps be used.
Wang et al. have demonstrated that several different single treat-
ments and, particularly, combinations of treatments can stimulate regen-
eration of sensoryﬁbers in the injured optic nerve and spinal cord. A next
step would be to demonstrate that such regeneration can continue untilFig. 2. Triple treatment of spinal cord injury as designed byWang et al. (2012). A preconditioni
ChABC,which is unstable at body temperature, is delivered into a cerebral ventricle every secon
is delivered to the subdural space at the site of injury using an osmotic minipump. The CTB lab
with permission).it reaches relevant brain areas or until signals from regenerating ﬁbers
can be relayed by intact pathways on the central side of the lesions,
and thus lead to functional improvements. For observations of such ef-
fects in the spinal cord model, electrophysiological studies would be
needed or the sciatic nerve would have to regenerate, as it may after
constriction injury, when sparing the perineurium around individual
bundles (see Olson, 1969).
Importance of repairing descending and ascending tracts
There is strong evidence that the corticospinal tract (CST) is of cru-
cial importance formost aspects ofwalking in humans, the only fully bi-
pedal primate species (Nielsen, 2002, 2003, Petersen et al., 2012a,
2012b, Castermans and Duvinage, 2013; Jain et al., 2013; Hiraoka and
Abe, 2007; Madhavan et al., 2011; Petersen et al., 2003, 2012a;
Sahyoun et al., 2004; Barthélemy et al., 2012). This is a good reason to
maintain focus on the rescue and repair of the corticospinal tract
(CST) also in rodent work, even if the relative role of the CST might be
lesser in these species. One should note, however, thatwhile rats, unlike
humans, with complete transection of the spinal cord can be made to
generate alternating walking-like movements with their hindlimbs
when given an appropriate sensory input (such as a moving treadmill)
and/or monoaminergic drugs, such ﬁndings do not prove that this is
how walking is carried out in intact animals. There are other examples,
such as heart rate control, where successively lower layers of functional
control are being activated when higher levels of control fail. There are
in fact indications that the corticospinal tract is of importance not only
for the forelimbs, but also for the hindlimbs, also in rats (Tsai et al.,
2005). It should also be noted that rats that have had the spinal cord le-
sioned at a thoracic level, will remain permanently paralyzed, as will
human beings.
As important as the CST may be for human walking, recovery
of function of the ascending sensory systems is equally important.
It is therefore gratifying to see that a degree of regeneration of these
systems has been accomplished by the two types of triple treatments
introduced by Wang et al. (2012).
Neural stem cells accompanied by a 10-factor cocktail
Recently, another group publishedwork inwhich they used a cocktail
of no less than 10 factors (NT-3, BDNF, EGF, βFGF, GDNF, PDGF,
αFGF, HGF, IGF-1 and calpain inhibitor) in a ﬁbrin gel to support rat or
human neural stem cells grafted to the completely transected spinal
cord of adult rats (Lu et al., 2012) (Fig. 3).ng crush of the sciatic nerve on one side is carried out a week before the spinal cord injury.
d day after injury via a stereotaxicallyﬁxed cannula. The Nogo receptor decoyNgR(310)-Fc
el is delivered to this injured sciatic nerve, proximal to the crush. (FromWang et al., 2012,
Fig. 3. Illustration from commentary by Popovich, 2012 of the grafting experiments by
Lu et al., 2012. A ﬁbrin gel containing 10 factors as listed and a suspension of neural
stem cells is injected into the gap of a T3 spinal cord transection 2 weeks after a
2 mm segment of the cord had been surgically removed. Lower half summarizes the
ﬁndings of multiple surviving cells contained where grafted, but sending axons long
distances into host spinal cord cranial and caudal to the injury site. From Popovich,
2012 with permission.
Fig. 4. BBB scores of hind limb function in grafted and control rats during 7 weeks post-
grafting. When the spinal cord was retransected at the interface between the cranial
host spinal cord and the grafted cells, the functional improvement was lost. Fig. 6G
from (Lu et al., 2012), with permission.
313L. Olson / Experimental Neurology 248 (2013) 309–315Complete T3 transection of the spinal cordwas carried out in ratswith
removal of a 2 mm segment of the cord. The researchers then dissociated
cells from E14 spinal cord tissue from transgenic rats ubiquitously ex-
pressing GFP. Such cell suspensions were mixed into a ﬁbrin matrix con-
taining the ten factors and the cell rich ﬁbrin mixture was injected into
the lesion cavities 2 weeks after spinal cord injury. While the trophic
cocktail probably exerted most of its effects on the cells in the ﬁbrin
matrix, it is known that implanted ﬁbrin glue loadedwith a trophic factor
(GDNF) can provide slow release of such a protein for about a week
(Cheng et al., 1998).
Two kinds of human neural stem cells were also grafted to rodents
using a similar approach. Grafted rodent cells and their processes
were detected by the presence of GFP and large numbers of a variety
of GFP-positive neurons and other cell types were found. The grafted
neurons extended remarkably large numbers of neurites both cranially
and caudally into the cut ends of the host spinal cord andmade synaptic
contacts with host spinal cord neurons. The grafted cells and their pro-
cesses were shown to carry electrical signals across the injury site lead-
ing to functional recovery that disappeared upon retransection of the
host spinal cord (Fig. 4).
It is known that the spinal cord distal to an injury that completely
separates it from contacts with the cranial stump is maintained in
reasonably good condition for decades of post-injury life in humans
(Bunge et al., 1993). Thus repair of the spinal cord by bridging tech-
niques that show effects in the completely severed spinal cord soon
after injury (Cheng et al., 1996; Lu et al., 2012) might also be applied
to patients with chronic spinal cord injury. In such cases, removal of
scar tissue on the spinal cord surfaces opposing the bridge implant
would almost certainly be needed. In rats, the multiple peripheral
nerve bridge technique, which uses ﬁbrin glue containing aFGF,
has also been applied to animals with chronic complete spinal cord
injury. By removal of scar tissue to expose fresh spinal cord tissue at
the surfaces of the spinal cord stumps, such bridges can restore a
degree of hind limb function (Fraidakis et al., 2004).Concluding remarks
We have come a long way since the days of Cajal and his contem-
poraries. There are now a number of different approaches to improve
recovery from partial as well as complete loss of continuity across a
spinal cord injury in rodent models. The complexity of the task has
lead to an increasing use of combinatory treatments, as exempliﬁed by
the studies by Wang et al. (2012) and Lu et al. (2012) discussed here.
There is cross-fertilization between research on traumatic brain injury
and spinal cord injury, which helps the development of novel strategies
and serves to validate results. Positive ﬁndings may ﬁnd use in both
areas, as well as in a number of other conditions in the central nervous
system. Indeed, there are accidents that cause a combination of traumatic
brain injury and spinal cord injury in the same individuals.
In the early 70s, studies of regeneration in the adult mammalian spi-
nal cord were rare, an example being the regeneration of descending
noradrenaline and serotonin axons followingmechanical or neurotoxin
lesions (Nygren et al., 1971). During the last 15 years,we havewitnessed
the recruitment of many laboratories, taking advantage of new basic
knowledge about trophic factors, nerve growth inhibitory factors, cell
and tissue transplantation procedures, themolecular biology of neurons,
glial cells, and stem cells, as well as transgenic animal models and a
plethora of biomedical and biotechnical achievements to diversify and
accelerate progress.
Several of the effective measures taken to treat the injured spinal
cord in animals cannot easily be translated into clinical trial protocols.
However, a number of clinical trials have been carried out, others are
ongoing, based on results from animal studies. Inspired and chal-
lenged by the basic, translational and clinical results to date, there is
good reason to assume that the trend of an increasing number of
researchers ready to tackle the “hard problem” – can the cut spinal
cord be repaired? – will continue. The road to the establishment
of clinically useful procedures may still be long, but the patience of
those working toward this goal is encouraging.
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